TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $73
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Yaron Werber has maintained a Buy rating on Ultragenyx Pharmaceutical and raised the price target from $61 to $73.

October 21, 2024 | 5:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen has increased its price target for Ultragenyx Pharmaceutical from $61 to $73, maintaining a Buy rating. This suggests a positive outlook for the company's stock.
The increase in the price target from $61 to $73 by TD Cowen indicates a positive sentiment towards Ultragenyx's future performance. Maintaining a Buy rating further supports the expectation of stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100